Evidence map›Paper›PMID 30399039›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2019

Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV: Implications for Treatment and Research.

Robert A Schnoll, Morgan Thompson, Katrina Serrano, Frank Leone, David Metzger, Ian Frank, Robert Gross, Karam Mounzer, Rachel F Tyndale, Jessica Weisbrot and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Bidirectional Associations among Nicotine and Tobacco Smoke, NeuroHIV, and Antiretroviral Therapy.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Robert A SchnollDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Morgan ThompsonDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Katrina SerranoDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Frank LeonePulmonary, Allergy, and Critical Care Division, University of Pennsylvania Presbyterian Medical Center, Philadelphia, PA.
David MetzgerDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Ian FrankDivision of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Robert GrossDivision of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Karam MounzerPhiladelphia Fight, Philadelphia, PA.
Rachel F TyndaleDepartment of Pharmacology and Toxicology, University of Toronto, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Jessica WeisbrotDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Miles MelineDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Ronald G CollmanPulmonary, Allergy and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA.
Rebecca L AshareDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
University of Pennsylvania · USPhiladelphia Fight · USUniversity of Toronto · CA

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6M
Penn Mental Health AIDS Research CenterP30MH097488 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI Karine Dube, Kelly L Jordan-Sciutto · 2013 to 2026
$23.5M
A Placebo Controlled Trial of Varenicline for Smoking among those with HIV/AIDSR01DA033681 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI SCHNOLL, ROBERT ADAM · 2012 to 2016
$2.5M
A Patient-Oriented Research Mentoring Program in Tobacco Dependence ResearchK24DA045244 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI Robert Adam Schnoll · 2018 to 2026
$1.7M
CIHR FDN-154294NIAID NIH HHS P30 AI045008NIDA NIH HHS K24 DA045244NIDA NIH HHS R01 DA033681NIMH NIH HHS P30 MH097488
6 · The paper itself

Abstract

backgroundThe nicotine metabolite ratio (NMR) is a biomarker that represents individual variation in the speed that nicotine is metabolized. The rate of nicotine metabolism alters smoking behavior (eg, amount) and has been validated for personalizing tobacco dependence medication selection to increase treatment efficacy and reduce treatment side effects in the general population of smokers. Although smoking rates are extremely high among those with HIV, the NMR has not been evaluated in this underserved population.

methodsWe used baseline data from a smoking cessation clinical trial for smokers with HIV (N = 131) to examine associations between NMR and demographic, smoking, disease-related, and psychological characteristics. Pearson r and analysis of variance were used to identify univariate correlates of NMR, which were then entered into a multiple linear regression model.

resultsIn univariate analyses, a higher NMR (faster nicotine metabolism) was associated with being white, and more cigarettes per day, nicotine dependence, exhaled carbon monoxide, and symptoms of depression and anxiety, and using efavirenz. In a multiple regression model, a higher NMR was associated with more cigarettes per day, higher anxiety symptoms, and efavirenz use.

conclusionsAs in other populations, faster nicotine metabolism was associated with the use of more cigarettes and higher anxiety symptoms. Notably, efavirenz use was associated with faster metabolism, which might make it harder to quit smoking for people with HIV treated with that medication. These findings could help guide further study and the clinical use of the NMR to personalize nicotine dependence treatment in this underserved population.

Indexed as

AdultAgedBiomarkersCarbon MonoxideCross-Sectional StudiesCytochrome P-450 CYP2A6FemaleHIV InfectionsHumansMaleMiddle AgedNicotineNicotinic AgonistsSmokingYoung AdultBiomarkersCarbon MonoxideCYP2A6 protein, humanCytochrome P-450 CYP2A6NicotineNicotinic Agonists

Identifiers

PMID30399039
PMCPMC6331237
OpenAlexW3017687726

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.